Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
IPCI

Intellipharmaceutics

$0.77

0.0029 (0.38%)

14:27
02/16/18
02/16
14:27
02/16/18
14:27
Downgrade
Intellipharmaceutics rating change at Maxim »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
BDX

Becton Dickinson

$233.54

1.42 (0.61%)

, ATHN

athenahealth

$125.53

-0.65 (-0.52%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

CRBP

Corbus Pharmaceuticals

$7.95

-0.25 (-3.05%)

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

IPCI

Intellipharmaceutics

$0.80

-0.02 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 02

    Feb

  • 06

    Feb

IPCI

Intellipharmaceutics

$0.80

-0.02 (-2.44%)

07:07
01/19/18
01/19
07:07
01/19/18
07:07
Initiation
Intellipharmaceutics initiated at H.C. Wainwright »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

$0.84

-0.0146 (-1.72%)

17:21
12/04/17
12/04
17:21
12/04/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

$1.15

0.025 (2.22%)

17:22
10/10/17
10/10
17:22
10/10/17
17:22
Earnings
Intellipharmaceutics reports Q3 EPS (8c), consensus (5c) »

Reports Q3 revenue $1.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

$0.85

-0.0478 (-5.31%)

07:09
09/25/17
09/25
07:09
09/25/17
07:09
Hot Stocks
Intellipharmaceutics receives CRL from FDA for Rexista NDA »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IPCI

Intellipharmaceutics

17:14
09/20/17
09/20
17:14
09/20/17
17:14
Hot Stocks
Intellipharmaceutics receives Nasdaq non-compliance notice »

Intellipharmaceutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IPCI

Intellipharmaceutics

$0.97

0.0216 (2.28%)

14:39
09/05/17
09/05
14:39
09/05/17
14:39
Hot Stocks
Intellipharmaceutics still 'strongly confident' in Rexista commercial potential »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IPCI

Intellipharmaceutics

$0.95

0.0184 (1.98%)

08:07
09/01/17
09/01
08:07
09/01/17
08:07
Hot Stocks
Intellipharmaceutics appoints Andrew Patient as CFO »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.